Related by context. All words. (Click for frequent words.) 90 Extending GestatioN 73 Phase III PREGNANT PROCHIEVE 73 PREGNANT PROCHIEVE Extending GestatioN 67 Phase III Pivotal 66 Completes Enrollment 66 Patient Enrollment 65 Randomized Double blind 65 Randomized Double Blind 65 Phase III Clinical Trial 65 Completes Patient Enrollment 64 Phase 2b Clinical Trial 64 First Patient Enrolled 64 IND Filing 64 Enrolling Patients 64 Pooled Analysis 64 Successfully Completes Phase 64 Controlled Study 64 FOLOTYN ® 64 Meets Primary Endpoint 64 Initiates Phase II 64 Demonstrates Positive 64 Refractory Angina 64 Drug Shows Promise 64 Immunomedics Announces 64 personalized cellular immunotherapy 64 Preclinical Data 64 recurrent metastatic ovarian cancer 63 pralatrexate injection folate analogue 63 RNAi Therapeutics 63 Initiates Clinical Trial 63 Study Evaluating 63 Clinical Trial Results 63 Nicotine Vaccine 63 Initiates Enrollment 63 Initiates Clinical 63 product platforms AZX# 63 Preclinical Study 63 candidate CRLX# 63 Phase IIb Trial 63 Phase 2a Clinical Trial 63 Pivotal Phase III 63 Agonist MABA program 63 Phase 2b Trial 63 Metastatic Melanoma 63 Cetrorelix 62 Oral Calcitonin 62 Pivotal Study 62 Cholesterol Lowering Drug 62 oncolytic virus therapies 62 MEK Inhibitor 62 Prospective Randomized 62 Phase 2a Trial 62 Novel Oral 62 oral prodrug 62 Tesetaxel 62 Initiate Phase III 62 Vicriviroc 62 Lupus Drug 62 individualized cellular immunotherapy 62 RNAi Therapeutic 62 II Clinical Trial 62 OMP #R# 62 DIRECT Trial 62 Randomized Phase 62 evaluating picoplatin 62 Xcytrin R 62 Submits Biologics License Application 62 Dupuytren Disease 62 Prostate Cancer Vaccine 62 NDA Submission 62 Placebo Controlled 62 YOUR LOCAL ANIMAL SHELTER 62 Initiate Phase 62 Pivotal Phase 61 Initiates Phase III 61 malignant mesothelioma Alfacell 61 TRANSDUR ™ 61 Glufosfamide 61 GATTEX TM 61 Oral Fingolimod 61 Degarelix 61 MKC# MKC# PP 61 Phase III Trial 61 ELADUR ™ 61 Controlled Trial 61 SPL# Gel vaginal microbicide 61 Clinical Trial Evaluating 61 Combination Treatment 61 ALISTA TM 61 Files IND 61 Drug Candidate 61 Acute Decompensated Heart Failure 61 evaluating mipomersen 61 Multicenter Randomized 61 Non Invasive Treatment 61 Anti Tumor Activity 61 Tezampanel 61 Therapeutic Competitors Companies 61 Advanced Melanoma 61 virus HCV protease inhibitor 61 Initiated Phase 61 Luramist TM 61 Sapacitabine 61 Study Shows Promise 61 REVIVE Diabetes 61 JAK Inhibitor 61 Phase IIb Clinical Trial 61 Empatic ™ 61 Phase Ib Clinical Trial 61 Randomized Phase II 61 Abstract Accepted 61 Migraine Drug 61 Demonstrates Sustained 60 Crofelemer budesonide foam 60 Commences Phase 60 Naive Patients 60 Presents Positive 60 Rheumatoid Arthritis Drug 60 Trial Evaluating 60 Drug Prevents 60 Efficacy Trial 60 Study Demonstrates 60 Pivotal Trial 60 Combination REOLYSIN R 60 investigational monoclonal antibody 60 HepeX B TM 60 Therapeutic Vaccine 60 Personalized Immunotherapy 60 Phase III Clinical Trials 60 Investigational Treatment 60 Completes Dosing 60 Anti Tumor 60 Submits NDA 60 pulmonology portfolio 60 telomerase therapeutic 60 Presents Preclinical Data 60 Evaluation Program CTEP 60 Tyrosine Kinase Inhibitor 60 Pulmonary Arterial Hypertension 60 Protease Inhibitor 60 Endologix Powerlink System 60 Prostate AdenoCarcinoma Treatment 60 PRN FDA Approves 60 phase IIb clinical 60 Cerebril TM 60 CYT# potent vascular disrupting 60 Curaxin CBLC# 60 Hedgehog Pathway Inhibitor 60 LibiGel ® 60 Deforolimus 60 Granted Orphan Drug 60 Prolongs Survival 60 blinded randomized placebo controlled 60 Study Showed 60 Begins Dosing 60 dimebon latrepirdine 60 Receives Orphan Drug Designation 60 BRIM2 60 Gout Drug 60 Archexin 60 Clinical Study Shows 60 Guidelines Recommend 60 cancer neuroendocrine tumor 60 Mipomersen 60 Phase 2b Study 60 Desvenlafaxine Succinate 60 SBIR Grant 59 phase IIb trial 59 Nanophase Announces 59 Custirsen 59 Small Molecule 59 ThermoDox ® clinical 59 targeted radiotherapeutic 59 Initiates Phase 59 EnteroMedics proprietary neuroblocking technology 59 Telik logo TELINTRA 59 First Patient Dosed 59 selective androgen receptor modulators 59 cardiac myosin activator omecamtiv 59 Schizophrenia Drug 59 non nucleoside inhibitor 59 Recurrent Breast Cancer 59 Phase 1b Clinical Trial 59 Hormone Receptor Positive 59 Multiple Ascending Dose 59 undergoing elective percutaneous 59 TBC# 59 Immunotherapeutic 59 Phase Ib II 59 Bazedoxifene 59 Demonstrates Efficacy 59 BLOOM Behavioral modification 59 Novel Inhibitor 59 Heart Failure Patients 59 Anti CD# Antibody 59 mecarbil 59 Telik Announces 59 Hematological Cancers 59 Transdermal Patch 59 trial evaluating PRX# 59 IL# PE#QQR 59 Worthwhile Cause 59 By JENNIFER LEARN 59 Tuberculosis Vaccine 59 Systemic Delivery 59 Single Dose 59 plus Copegus R 59 Shows Promising 59 Clostridium difficile Infection 59 Glatiramer Acetate 59 Treatment Regimen 59 Complicated Skin 59 Intervention Effectiveness 59 Phase IIa Clinical Trial 59 Adjuvant Treatment 59 Elagolix 59 Pertuzumab 59 Teva Provides Update 59 Receives Approvable Letter 59 Hormone Refractory Prostate Cancer 59 Intracranial Aneurysms 59 Matrix Phase 2b 59 INSPIRE Trial Phase III 59 Metastatic Prostate Cancer 59 Mg Usa 59 Dose Escalation 59 delivery polymer matrix 59 Hypertensive Patients 59 See CLINICAL PHARMACOLOGY 59 JAK2 Inhibitor 59 Hematology Molecular Pathology 59 Therapeutic Efficacy 59 Molecular Diagnostic Test 59 FDA Approvals 59 Relapsing Multiple Sclerosis 59 Phase 1b clinical trials 59 PerkinElmer Introduces 59 PSMA ADC 59 NicVAX TM 59 OAB overactive bladder 59 Aptamer 59 CHANGE TEXT 59 Ovitrelle R Serostim 59 Milestone Payment 59 small molecule thrombopoietin 59 Treatment Shows Promise 59 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 59 oral ghrelin agonist 58 Romidepsin 58 Therapy Improves 58 oral nucleoside analogue 58 Commence Phase 58 Achieves Primary Endpoint 58 Effectively Treats 58 Treatment Naïve 58 allosteric modulator PAM 58 Second Pivotal Phase 58 MEND CABG 58 VICTOR E3 58 Asthma Treatment 58 Licenses Novel 58 Shows Statistically Significant 58 FDA APPROVES 58 LymphoStat B belimumab 58 PDX pralatrexate 58 Motesanib 58 candidate REP# 58 ENABLE Phase 2 58 delivers fluocinolone acetonide FA 58 including eniluracil ADH 58 Improves Survival 58 Pivotal Clinical Trial 58 Aeolus Pharmaceuticals Announces 58 Relapsed Multiple Myeloma 58 modified glutathione analog 58 acyclovir Lauriad R 58 apricitabine ATC 58 novel orally inhaled 58 Silodosin 58 Cardiac Resynchronization 58 Phase IIIb 58 Receives Orphan Drug 58 product Fentanyl TAIFUN 58 Completes Patient Enrolment 58 SPRYCEL ® 58 Phase #/#a 58 Chemotherapeutic Agents 58 Epratuzumab 58 Aggressive Reduction 58 Multicenter Randomized Double 58 Zicam Extreme 58 Shows Promise Against 58 HCV NS5B polymerase 58 CCX# B 58 Ocrelizumab 58 APEX PD 58 TRANSDUR ® 58 Aurora Kinase 58 Frozen Shoulder syndrome Adhesive 58 VIVITROL ® 58 BLP# Liposome Vaccine 58 MT#/MEDI-# 58 intravesical infusion therapy 58 includes TOLAMBA TM 58 Subgroup Analysis 58 Cardiac Biomarkers 58 Improves Outcomes 58 dependent kinase inhibitor 58 Renal Cell Carcinoma 58 Slows Progression 58 Panzem R 58 SPEAR Study 58 Blood Pressure Reduction 58 NOTE POSIDUR ™ 58 Phase #b/#a clinical 58 VEGFR2 inhibitor 58 Chronic Heart Failure 58 Patient Enrolment 58 Trandolapril 58 TB Vaccine 58 BioSante Pharmaceuticals Announces 58 Randomized Controlled Trial 58 HDAC Inhibitor 58 Dose Ranging 58 Mylan Receives Approval 58 Antigen Specific 58 Testosterone MDTS ® 58 compound INCB# 58 NU# direct 58 phase IIb study 58 Scottish Motion Tabled 57 Myocet 57 MKC# MT 57 NPC 1C 57 Angiocept 57 Aganocide 57 Investigational Compound 57 phase III isavuconazole 57 ADVANCE ILLUMINATE 57 Cerebral Amyloid Angiopathy 57 Cloretazine ® 57 STRIDE PD 57 Romiplostim 57 ATRA IV 57 registrational Phase 57 KNS # 57 Tanespimycin 57 Cannabinor 57 Spinal Fractures 57 Enrolls First 57 cathepsin K inhibitor 57 mertansine 57 FDA Accepts 57 MAGE A3 ASCI 57 HuMax EGFr 57 GVAX ® 57 Zenvia ™ 57 ongoing Phase 1b 57 R Saizen R 57 Bayer HealthCare Onyx Pharmaceuticals 57 Eluting Stent 57 Cethrin R 57 Aeterna Zentaris Inc 57 PANVAC VF 57 Phase Ib clinical 57 Anticancer Agent 57 PDE4 inhibitor 57 Randomized Study 57 Initiate Clinical Trial 57 Safinamide 57 Humanized Anti 57 Aflibercept 57 Patients Suffering 57 Dose Ranging Study 57 kidney urologic 57 Appears Safe 57 AEG# 57 Daclizumab 57 RCW Breast Cancer 57 Initiates Phase 2b 57 Meta Analysis 57 Brentuximab Vedotin SGN 57 HCD# [002] 57 TACI Ig 57 Solazed TM 57 Augment TM 57 Ridaforolimus 57 Treat Heart Failure 57 candidate XP# 57 Expanded Indication 57 Hepatocellular Carcinoma 57 mGluR5 negative 57 Dapagliflozin 57 NMT Medical Announces 57 Amigal TM 57 Factor VIIa 57 Osteoporosis Drug 57 EXECUTIVE SUMMARY II 57 Treatment Experienced 57 SinuNase TM 57 Panzem R NCD 57 BENLYSTA TM 57 Clot Busting 57 Pralatrexate 57 Picoplatin Efficacy After 57 Systemic Sclerosis 57 LUX Lung 57 lintuzumab SGN 57 vapreotide acetate 57 multicenter Phase II 57 Melphalan 57 Monoclonal Antibody 57 Demonstrates Potential 57 ERBITUX cetuximab 57 Recurrent Glioblastoma 57 Capsulitis 57 XL# anticancer compounds 57 Metastatic Renal Cell Carcinoma 57 Adult Stem Cell Therapy 57 Non Invasive 57 dose escalation clinical 57 PROVENGE sipuleucel T 57 TELINTRA R 57 Testosterone MDTS R 57 Hsp# Inhibitor 57 Microplasmin 57 recombinant PSMA vaccine 57 worsening thrombocytopenia 57 HQK 57 Namenda Memantine HCl 57 investigational humanized monoclonal antibody 57 Phase Ib study 57 oral Janus kinase 57 Sirolimus Eluting Stent 57 novel VDA molecule 57 Antipsychotic Drug 57 Peginterferon Alfa 2a 57 Advanced Renal Cell 57 aflibercept VEGF Trap 57 MKC# 57 Entry Inhibitor 57 AAG geldanamycin analog 56 ONCONASE R 56 GRNOPC1 contains 56 comparing alemtuzumab 56 SUCCEED trial 56 Iloperidone 56 Oral Spray 56 Metastatic Colorectal Cancer 56 evaluating Actimmune 56 CYP#A# CYP#D# 56 Long Term Efficacy 56 Platelet Inhibition 56 Phase Ib clinical trials 56 PNP inhibitor 56 ENDEAVOR IV 56 PEGINTRON TM 56 atypical Hemolytic Uremic Syndrome 56 CHAMPION PCI 56 Demonstrates Significant 56 Perifosine KRX 56 oral dual endothelin 56 Phase IIB 56 Sports Tide Prothro 56 Engl J Med 56 interferon alpha IFN 56 Stereotactic Body Radiation Therapy 56 CRMD# 56 Patent Covering 56 Phase 2a clinical 56 Diamyd Medical Diamyd 56 Elestrin ® 56 CCR5 mAb 56 evaluating tivozanib 56 randomized controlled multicenter 56 tiapamil 56 Cancer Vaccines 56 Abciximab 56 6 sulfatase 56 opioid induced bowel dysfunction 56 Collaborators Publish 56 Patients Treated With 56 ENESTnd 56 Nasdaq ACHN 56 GW# [003] 56 CINQUIL 56 Phase III multicenter 56 IIa Clinical Trial 56 SinuNase ™ 56 Bosutinib 56 Physician Insights 56 candidates Azedra TM 56 oral proteasome inhibitor 56 Chronic Myeloid Leukemia 56 brand ciclesonide HFA 56 RANK Ligand inhibitor 56 nasal calcitonin product 56 Oral Insulin 56 lucinactant 56 pharmacogenomic translational research 56 Advaxis Phase 56 PEGylated Fab fragment 56 ACTEMRA TM 56 Rotavirus Vaccine 56 PHX# 56 SCIB1 56 registrational trial 56 docetaxel Taxotere R 56 KRN# 56 number NCT# ClinicalTrials.gov 56 NASH Huntington 56 Chronic Hepatitis C 56 rALLy clinical trial 56 Pivotal Phase II 56 HGS ETR1 mapatumumab 56 Medoxomil 56 oral calcitonin licensed 56 myocardial infarction ventricular fibrillation 56 Phase 2a Study 56 EVIZON TM 56 ACAPODENE 56 Plicera 56 TNF Tumor Necrosis Factor 56 IMPDH inhibitor 56 IND Application 56 Central Retinal Vein 56 multicenter Phase 56 Nanobody 56 OTCBB PYTO 56 Acute Myocardial Infarction 56 Inc. Nasdaq OXGN 56 2 methoxyestradiol 56 3 registrational trial 56 ThermoDox R 56 elotuzumab 56 HURRICANE WATCH AND 56 Diabetic Macular Edema DME 56 Varespladib 56 Pirfenidone 56 Syndax Pharmaceuticals Inc. 56 IMC #B 56 Antitumor Activity 56 Fondaparinux 56 LymphoStat B TM 56 Plaque Psoriasis 56 evaluating Prochymal 56 Previously Untreated 56 refractory chronic lymphocytic 56 FEMALE NON.AGG.PHYS.FORCE 56 Oral NKTR 56 Pafuramidine 56 Horizant ™ 56 Tumor Response 56 LEVADEX TM 56 ARIXTRA R 56 IMPACT DCM trial 56 Diabetic Macular Edema 56 HIV Integrase 56 DNA Microarray 56 Inhalation Solution 56 CEQ# 56 Newly Diagnosed 56 autologous cellular immunotherapy 56 YONDELIS 55 Shigamabs R 55 qualitative serum 55 Glycopyrrolate 55 TM Drug Eluting 55 EDEMA3 55 5 HT3 antagonist 55 toenail onychomycosis 55 Syncria R 55 Dasatinib 55 lead Aganocide compound 55 HER2 Positive 55 clinical trials Archexin 55 solid tumors ZYBRESTAT 55 RhuDex 55 Mg Uk 55 CEL SCI Phase III 55 agonistic human 55 EOquin TM phase 55 Prognostic Value 55 Dose Finding 55 Early Relapsing Multiple 55 PEGylated docetaxel 55 Prodrug 55 Carotid Revascularization Endarterectomy vs. 55 induced macular edema 55 anti VEGF aptamer 55 HCV SPRINT 55 pan histone deacetylase 55 Psoriasis Drug 55 phase IIa 55 RELOVAIR ™ 55 DUROS 55 AVOREN 55 Dementia Related Psychosis 55 Unresectable 55 receiving INTRON 55 Anchor Therapeutics 55 forodesine purine nucleoside phosphorylase 55 Vitrasert R 55 Slow Progression 55 evaluating pirfenidone 55 ALN VSP Phase 55 initiated Phase Ib 55 Taro Receives 55 evaluating intravenous picoplatin 55 fosbretabulin 55 Zenvia Phase III 55 randomized controlled Phase 55 occlusion PAO 55 Monotherapy 55 humanized therapeutic 55 hypertrichosis occurred 55 IMPACT DCM 55 Study Evaluates 55 Luveniq 55 FOLFOX6 chemotherapy regimen 55 Alzhemed TM 55 unique alkylating agent 55 THAT ARE DIFFICULT TO 55 VICTOR E1 55 External Beam 55 RhuDex R 55 Pimavanserin 55 sunitinib Sutent ® 55 Paclitaxel Carboplatin 55 Angiotensin Converting Enzyme 55 E1 INT TM 55 Bremelanotide 55 Enzastaurin 55 R roscovitine CDK cyclin 55 Decompensated Heart Failure 55 Cutaneous T 55 LUNESTA TM 55 erlotinib Tarceva ® 55 PROTEGE 55 Phase Ib IIa 55 forodesine 55 Phase III ADT 55 novel synthetic peptide 55 NEBIDO VANTAS SUPPRELIN LA 55 class mGluR5 inhibitor 55 PF # [002] 55 albiglutide 55 Pruvel TM 55 TRAIL receptor antibodies 55 Intravitreal 55 Iluvien ® 55 Vaccine Candidate 55 PHASE III 55 Ophena TM 55 metastatic castrate resistant 55 Sular formulation 55 Milestone Payments 55 oral ridaforolimus 55 Liposomal 55 OvaRex ® MAb 55 antibody MAb 55 particularly SANCTURA XR 55 IMiD 55 Peginterferon alfa 2b 55 Vytorin combines 55 Clinically Tested 55 placebo controlled Phase 55 TNFerade TM 55 phase Ib clinical 55 Soft Tissue Sarcoma 55 IMiDs R 55 Omacetaxine 55 THERAVANCE ® 55 PNT# 55 Malignant Glioma 55 R lenalidomide 55 Zorbtive TM 55 Fast Track Status 55 Phase III Psoriasis 55 IMPACT IMmunotherapy 55 humanized interleukin 6 55 Adenoma 55 dextromethorphan quinidine 55 Hemispherx flagship products 55 Myelofibrosis 55 novel histone deacetylase 55 Detecting Breast Cancer 55 Vion Pharmaceuticals 55 IgG1 monoclonal antibody 55 Atypical Hemolytic Uremic Syndrome 55 Bruker Introduces 54 Severe Sepsis 54 Ranolazine 54 polymerase inhibitor 54 candidates Augment ™ 54 Lysteda 54 Confirmatory Phase 54 novel chimeric natriuretic 54 Recombinant Human 54 Preclinical Models 54 CTA# Injection 54 Detect Lung Cancer 54 endoscopic autofluorescence imaging 54 glucokinase activator 54 Homspera TM 54 phase IIIb 54 EXPLORE Xa 54 Argatroban 54 5 fluorouracil leucovorin 54 class anticancer quinolone 54 interferon gamma 1b 54 Synta Announces 54 Ascent Therapeutics 54 administering VIVITROL 54 REVENUE PER VEHICLE RETAILED 54 riociguat 54 dasatinib Sprycel ® 54 rxRNA 54 PROVENGE ® 54 Phase IIIb clinical 54 angiotensin analog 54 Treatment Naive Patients 54 BEMA Granisetron 54 RECOTHROM R 54 CR# vcMMAE 54 Genotyping Test 54 Teplizumab 54 Announces Tentative Approval 54 HuMax TAC 54 EDEMA4 54 Renal Impairment 54 & Tuition Reimbursement 54 Onyx Pharmaceuticals Announces 54 Endovascular Valve Edge 54 albiglutide currently 54 multicenter phase 54 serum phosphorous 54 recurrent glioblastoma multiforme 54 Paroxysmal Atrial Fibrillation 54 MUSICAL Kelsey Grammer 54 multi kinase inhibitor 54 Respiratory Virus 54 bone marrow reticulin deposition 54 DermTech International 54 pharmacodynamic profiles 54 Spiegelmer ® 54 COSIRA trial 54 triggers apoptosis programmed 54 pivotal bioequivalence 54 alfa 2a 54 accumulate preferentially 54 Edge STudy 54 tramiprosate Alzhemed TM 54 Interferon beta 1a 54 Shows Efficacy 54 orally administered inhibitor 54 sapacitabine CYC# 54 Allovectin 7 R 54 Neovascular Age Related Macular 54 Proc Am Soc 54 Levoleucovorin 54 carcinoma mCRC 54 Insulin Glargine 54 monoclonal antibody IgG1 Mab 54 Clolar ® 54 IMPACT DCM clinical 54 MEVACOR 54 Phase IIIb study 54 D aspartate NMDA receptor 54 complement inhibitor eculizumab 54 Gentamicin Surgical Implant 54 Investigational Oral 54 Amrubicin 54 Parathyroid Hormone 54 miconazole Lauriad R 54 AVN# Phase 54 Cintredekin Besudotox 54 known dihydropyrimidine dehydrogenase 54 Nanoemulsion 54 Refractory Peripheral T 54 cladribine Cladribine Tablets 54 Ovarian Cancers 54 Hepatocellular Carcinoma HCC 54 Interferon Alpha 54 label multicenter Phase 54 phase Ib 54 CONQUER OB 54 Genetic Variants 54 PrevOnco ™ 54 treatment naïve genotype 54 Wound Dressing 54 LEUKINE 54 investigational oral inhibitor 54 Therapy Reduces 54 Alzheimer disease cognitive impairment 54 Heterozygous Familial Hypercholesterolemia 54 Targeted Therapies 54 Companion Diagnostic 54 Relapsed Refractory 54 InNexus Biotechnology 54 SAFLUTAN 54 investigational protease inhibitor 54 formerly LymphoStat B 54 Liprotamase 54 Uterine Fibroid Embolization 54 PDUFA Date 54 pharmacokinetic PK study 54 Adenosine Therapeutics 54 BRIM3 54 Vidofludimus 54 Alfacell proprietary ribonuclease 54 metastatic colorectal carcinoma 54 Empatic TM 54 Capsules CII 54 Vascular Disrupting Agent 54 retinal vein occlusion induced 54 PREOS R 54 aneurysms AAA 54 Gene Mutation Linked 54 Eltrombopag 54 Chemical Entity NCE 54 PLK1 SNALP 54 relapsing remitting MS RRMS 54 RESTORE CLI trial 54 Chronic Lymphocytic Leukemia 54 signal detection CTSD 54 Ixabepilone 54 cetuximab Erbitux R 54 relapsed refractory multiple myeloma 54 adrenergic regulation 54 generation purine nucleoside 54 Annamycin 53 Sipuleucel T 53 Placebo Controlled Trial 53 Eszopiclone 53 approved incretin mimetic 53 Tasimelteon 53 HepaSphere 53 ARCHITECT HIV 53 Elvitegravir 53 SHOULD THIS OCCUR 53 Newly Diagnosed Multiple Myeloma 53 ® chorionic gonadotropin 53 beta 1a 53 Exherin TM 53 Simulect 53 Inhalation Aerosol 53 liver resection surgeries 53 evaluating satraplatin plus 53 Naproxcinod 53 VitiGam 53 selective immunoproteasome inhibitor 53 keloid scarring 53 evaluating satraplatin 53 data management Clintrial 53 Successfully Treats 53 J Gerontol 53 Pruvel ™ prulifloxacin 53 G5 DDR# 1Gig kits 53 Hypertrophy 53 anti CD3 monoclonal 53 liposomal formulation 53 Agers neo pagans 53 receptor tyrosine kinase inhibitor 53 double blinded placebo 53 metastatic androgen independent 53 Maribavir 53 Files Investigational 53 5 FU leucovorin 53 Dose Limiting Toxicity DLT 53 HCV RESPOND 2 53 Temsirolimus 53 Systematic Review 53 Fabry Disease 53 FACTIVE R gemifloxacin 53 Lymphocytic 53 randomized Phase IIb 53 Generic Versions 53 PROTECT AF 53 Cellegesic TM nitroglycerin ointment 53 Xanafide 53 Relapsing Remitting Multiple Sclerosis 53 HCl Tablets 53 selective modulator 53 Symbioscience WISDOM PANEL 53 Cell Lymphoma 53 Generic Version 53 multicenter multinational 53 IAP inhibitors 53 Hypoactive Sexual Desire Disorder 53 Drug Applications INDs 53 recombinant biopharmaceutical 53 Traficet EN 53 proteasome inhibitor 53 Boceprevir 53 Pegloticase 53 Phase 1b clinical 53 dose escalation Phase 53 Reveals Tracklisting 53 Node Positive 53 FEMALE AGG.PHYS.FORCE 53 drug ISA# 53 Pharmacokinetics PK 53 J Am Acad 53 JZP 53 Phase 1a clinical 53 rasagiline tablets 53 TO AVOID PREGNANCY WHILE 53 allosteric modulator NAM 53 VYVANSE TM lisdexamfetamine 53 terlipressin 53 CYP#A# substrate 53 ISTODAX ® 53 Primary Hypercholesterolemia 53 Ecallantide 53 AN# topical anti 53 irinotecan doxorubicin oxaliplatin paclitaxel 53 Non Alcoholic Steatohepatitis 53 IMA# 53 intravenous RSD# 53 NEW YORK TIMES BESTSELLER 53 SMALL COMPANY OUR COMPARATIVELY 53 Coadministration 53 Anthracycline 53 BR.# 53 Squamous Cell Carcinoma 53 ZEVALIN ® 53 influenza BCX# purine nucleoside 53 DAY WHAT WOULD 53 NS5B polymerase 53 Pharmacogenetic 53 Anti VEGF 53 CDK cyclin dependent 53 Alemtuzumab 53 HGS ETR1 53 overactive bladder AA# 53 Seasonal Influenza Vaccine 53 relapsed MM 53 MEND CABG II 53 systemic anaplastic large 53 Saforis 53 Adjuvant Chemotherapy 53 evaluating T DM1 53 NASCAR SPRINT CUP RACE 53 MEDICINES THAT MAKE 53 OvaRex R 53 ELND# 53 CAMMS# 53 imetelstat GRN#L 53 catheter occlusion 53 indolent follicular non 53 huC# DM4 53 ELACYT 53 Zalypsis 53 Kuvan TM sapropterin 53 PURCHASE WILL NOT INCREASE 53 CML CP 53 Myocardial Ischemia 53 Lixisenatide 53 GOUT 53 develop HBV reactivation 53 metastatic colorectal 53 Curaxin 53 RxKinetix 53 plus dacarbazine 53 budesonide foam 53 PREVAIL 53 Corgentin 53 Anticancer Agents 53 nephropathic cystinosis 53 ragweed allergy immunotherapeutic 53 Drug Submission 53 ZACTIMA 53 Lenocta TM 53 Lubiprostone 53 oral picoplatin 53 TNFerade ™ 53 CASTLEBAY IRISH PUB 53 Subarachnoid Hemorrhage 53 Nanobody R 53 metastatic castration resistant 53 cisplatin gemcitabine 53 Nitazoxanide 52 injectable enzyme 52 nilotinib Tasigna ® 52 RRa Radical 7 52 AKT inhibitor 52 intravenous belinostat 52 LHRH receptor positive 52 CLARITY study 52 R tiagabine hydrochloride NUVIGIL 52 NONINFRINGEMENT TITLE MERCHANTABILITY OR 52 Submits IND 52 reslizumab 52 Antifungals 52 candidate AQ4N 52 FDA Approvable Letter 52 PEGINTRON REBETOL combination 52 BCG refractory carcinoma